<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02578498</url>
  </required_header>
  <id_info>
    <org_study_id>H-15009662</org_study_id>
    <nct_id>NCT02578498</nct_id>
  </id_info>
  <brief_title>Glucagon Efficiency After High and Low Carbohydrate Diet</brief_title>
  <acronym>HiLoCarb</acronym>
  <official_title>Glucagon Efficiency After High and Low Carbohydrate Diet</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hvidovre University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Danish Diabetes Academy</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hvidovre University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      No studies have investigated if the dietary composition of carbohydrate influences the
      glycaemic effect of single and multiple boluses of subcutaneous low-dose glucagon. Further,
      the recommended diet composition to patients with type 1 diabetes has not been thoroughly
      validated. Many patients with type 1 diabetes practice low carbohydrate eating patterns due
      to the assumption that this diet can reduce fluctuations in plasma glucose. Before glucagon
      can be used as an add-on to intensive insulin treatment, these aspects need to be elucidated.
      The purpose of this study is to determine, whether diet composition of carbohydrate affects
      the glycogen stores in the liver and affects the glucose response of glucagon during
      hypoglycaemia.

      HYPOTHESIS: In patients with type 1 diabetes, the glucose response of a single bolus of
      low-dose glucagon is not associated with diet carbohydrate content.

      AIM: The aim is to investigate how one week of high- compared to low-carbohydrate diet
      influence the glycaemic response of low-dose glucagon in patients with insulin pump treated
      type 1 diabetes. The secondary aim is to investigate how two dietary intervention weeks
      differ in the incidence of hypoglycaemia, postprandial hyperglycaemia, and daily glucose
      excursions.

      DESIGN:A non-blinded two-way cross-over, randomized study will be conducted. After
      participants have given an informed consent, they will go through four steps: 1) screening
      visit 2) Run-in period, 3) first meal intervention for one week finalizing with one study
      visit and 4) second meal intervention for one week finalizing with another study visit.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2015</start_date>
  <completion_date type="Actual">July 2016</completion_date>
  <primary_completion_date type="Actual">March 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incremental area under the glucose curve</measure>
    <time_frame>0-240 minutes</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Peak glucose value</measure>
    <time_frame>within 240 minutes</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Glucagon concentration</measure>
    <time_frame>0-240 min.</time_frame>
    <description>Blood samples</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insulin concentration</measure>
    <time_frame>0-240 min.</time_frame>
    <description>Blood samples</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Triglycerides concentration</measure>
    <time_frame>0-240 min.</time_frame>
    <description>Blood samples</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Katekolamine concentration</measure>
    <time_frame>0-240 min.</time_frame>
    <description>Blood samples</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ketone bodies concentration</measure>
    <time_frame>0-240 min.</time_frame>
    <description>Blood samples</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Free fatty acids concentration</measure>
    <time_frame>0-240 min.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nausea</measure>
    <time_frame>0-240 min.</time_frame>
    <description>Visual analog scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Headache</measure>
    <time_frame>0-240 min.</time_frame>
    <description>Visual analog scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hypoglycemia symptoms</measure>
    <time_frame>0-240 min.</time_frame>
    <description>Visual analog scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vomit</measure>
    <time_frame>0-240 min.</time_frame>
    <description>Occurence</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma glucose variation</measure>
    <time_frame>Two weeks</time_frame>
    <description>A continuous glucose monitor register daily glucose variation levels for two weeks.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Type 1 Diabetes</condition>
  <condition>Hypoglycemia</condition>
  <arm_group>
    <arm_group_label>High carbohydrate diet</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>high carbohydrate intake</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low carbohydrate diet</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>low carbohydrate intake</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>High carbohydrate intake</intervention_name>
    <description>Carbohydrate intake &lt; 50 gram</description>
    <arm_group_label>Low carbohydrate diet</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Low carbohydrate intake</intervention_name>
    <description>Carbohydrate intake &gt; 250 gram</description>
    <arm_group_label>High carbohydrate diet</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18 - 70 years

          -  T1D ≥ 3 year

          -  BMI 20-27 kg/m2

          -  CSII ≥ 1 year

          -  HbA1c &lt; 69 mmol/mol (8.5 %)

          -  C-peptide negative (&lt; 60 pmol/l)

          -  Hypoglycemia awareness (self-reported)

          -  Use of carbohydrate counting and the insulin pump bolus calculator for all meals

        Exclusion Criteria:

          -  Allergy or intolerance to lactose or Glucagen®(Novo Nordisk, Bagsværd, DK)

          -  Impaired renal function (eGFR &lt; 60 ml/min/1.73m2)

          -  Liver disease with ALAT &gt; 2.5 times the upper limit of the reference interval

          -  Use of anti-diabetic medicine (other than insulin), corticosteroids or other drugs
             affecting glucose metabolism during the study period or within 30 days prior to study
             start

          -  Known or suspected alcohol or drug abuse

          -  Other concomitant medical or psychological condition that according to the
             investigator's assessment makes the patient unsuitable for study participation

          -  Females who are pregnant, breast-feeding or intend to become pregnant or are not using
             adequate contraceptive methods.

          -  Inability to understand the patient information and to give informed consent.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kirsten Nørgaard, MD, DMSc</last_name>
    <role>Study Chair</role>
    <affiliation>Hvidovre University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hvidovre University Hospital</name>
      <address>
        <city>Hvidovre</city>
        <zip>2650</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>October 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 14, 2015</study_first_submitted>
  <study_first_submitted_qc>October 15, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 19, 2015</study_first_posted>
  <last_update_submitted>August 15, 2016</last_update_submitted>
  <last_update_submitted_qc>August 15, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 16, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hvidovre University Hospital</investigator_affiliation>
    <investigator_full_name>Ajenthen Ranjan</investigator_full_name>
    <investigator_title>MD, PhD student</investigator_title>
  </responsible_party>
  <keyword>glucagon</keyword>
  <keyword>Carbohydrate diet</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
    <mesh_term>Hypoglycemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glucagon</mesh_term>
    <mesh_term>Glucagon-Like Peptide 1</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

